[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532915":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":32,"responsibleParty":75,"collaborators":20,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":20,"studyType":92,"phases":93,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Zuyderland Medisch Centrum","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Medical grade honey formulation (MGH) (L-Mesitran®) for CIN II","EXPERIMENTAL","Daily application of 5 grams (with applicator) for 3 months. Then weekly application (5 grams with applicator) for 3 months.",[13],"Drug: Medical grade honey formulation (MGH) (L-Mesitran®)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Medical grade honey formulation (MGH) (L-Mesitran®)","Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.",[9],null,[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Jordy Mongula, dr.","CONTACT","+31621872080","19264","j.mongula@zuyderland.nl",{"name":29,"role":24,"phone":30,"phoneExt":20,"email":31},"Jasmijn Prop, Drs.","+31524787337","j.prop@zuyderland.nl",[33,55],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Zuyderland MC","RECRUITING","Heerlen","Limburg","6149 PC","Netherlands","NL",{"type":42,"coordinates":43},"Point",[44,45],5.98154,50.88365,{"lat":45,"lon":44},[48,50,53],{"name":49,"role":24,"phone":25,"phoneExt":20,"email":27},"Jordy Mongula, Doctor",{"name":51,"role":24,"phone":52,"phoneExt":20,"email":31},"Jasmijn Prop, Master of Science (medicine)","+3624787337",{"name":49,"role":54,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":57,"city":58,"state":37,"zip":59,"country":39,"countryCode":40,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Maastricht University Medical Centre+","NOT_YET_RECRUITING","Maastricht","6229 HX",{"type":42,"coordinates":61},[62,63],5.68889,50.84833,{"lat":63,"lon":62},[66,70,73],{"name":67,"role":24,"phone":68,"phoneExt":20,"email":69},"Peggy De Vos - van Steenwijk, Doctor","+31641240628","peggy.de.vosvansteenwijk@mumc.nl",{"name":71,"role":24,"phone":72,"phoneExt":20,"email":31},"Jasmijn Prop, Master in Science","+31624787337",{"name":71,"role":74,"phone":20,"phoneExt":20,"email":20},"SUB_INVESTIGATOR",{"type":76,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100532915","phase-1-effect-of-honey-for-cin-ii-100532915",false,"NCT06219018","Effect of Honey For CIN II","The Effect of Medical Grade Honey (L-Mesitran) for Cervical Intraepithelial Neoplasia-II","HoneyForCINII","Inclusion Criteria:\n\n* Women 18-40 years\n* Primary CIN II confirmed histologically in the biopsy on colposcopic examination\n* Sufficient mastery of the Dutch language\n\nExclusion Criteria:\n\n* Simultaneous abnormality in columnar epithelial cells (AIS).\n* Hr-HPV negative cytology\n* Immunosuppressant use\u002FAutoimmune disease (HIV, CVID)\n* History of cervical carcinoma or previous treatment for CIN (LLETZ or imiquimod)\n* Pregnancy or the intention to become pregnant during the study period\n* Legal incompetence\n* Known allergies to honey",true,"FEMALE","18 Years","40 Years",{"count":90,"type":91},60,"ESTIMATED","INTERVENTIONAL",[94,95],"PHASE1","PHASE2","The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.",[98,99],"Cervical Intraepithelial Neoplasia-II","High Risk Human Papillomavirus",[101],"Honey CINII","2025-06-13",{"date":104,"type":105},"2025-06-18","ACTUAL",{"date":107,"type":105},"2024-12-30",{"date":109,"type":91},"2027-12-01",{"name":5,"class":6},2]